Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, ≥ 18 years of age.
Locally advanced or recurrent (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.
Presence of epidermal growth factor receptor (EGFR) mutations in tumours.
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria.
European Cooperative Oncology Group (ECOG) performance status ≤ 2.
You may not be if
Prior exposure to agents directed at the human epidermal receptor (HER) axis (eg, but not limited to erlotinib, gefitinib, cetuximab, or trastuzumab).
Prior chemotherapy or systemic anti-neoplastic therapy for advanced disease.
Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or active gastroduodenal ulcer disease.
Any inflammatory changes of the surface of the eye.
≥ Grade 2 peripheral neuropathy.
History of any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.
Brain metastasis or spinal cord compression that has not yet been definitely treated with surgery and/or radiation, or treated but without evidence of stable disease for at least 2 months.
Human immunodeficiency virus (HIV) infection.
Pregnant, nursing, or lactating women.
Clareo Health | A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
